부산대학교 도서관

Piette, Yves ; Reynaert, Valerie ; Vanhaecke, Amber ; Bonroy, Carolien ; Gutermuth, Jan ; Sulli, Alberto ; Cutolo, Maurizio ; Smith, Vanessa

In Autoimmunity Reviews June 2022 21(6)

Dabizzi, Emanuele; Saccomani, Marco Deganello; Di Toma, Michele; Gatti, Simona; Illiceto, Maria Teresa; Isoldi, Sara; Maino, Marta; Pellegrino, Maristella; Strisciuglio, Caterina; Renzo, Sara ; Scarallo, Luca ; Antoniello, Luca Maria ; Bramuzzo, Matteo ; Chiaro, Andrea ; Cisarò, Fabio ; Contini, Anna Chiara Iolanda ; De Angelis, Gian Luigi ; De Angelis, Paola ; Di Nardo, Giovanni ; Felici, Enrico ; Iuliano, Silvia ; Macchini, Francesco ; Mantegazza, Cecilia ; Martelossi, Stefano ; Oliva, Salvatore ; Parrinello, Flavia ; Rea, Francesca ; Pizzol, Antonio ; Romano, Claudio ; Russo, Giusy ; Sansotta, Naire ; Lionetti, Paolo

In Digestive and Liver Disease May 2022 54(5):572-579

van Ewijk R; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands. r.vanewijk-2@prinsesmaximacentrum.nl.; Chatziantoniou C; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.; Image Sciences Institute, UMC Utrecht, Utrecht, The Netherlands.; Adams M; Department of Paediatric Oncology, Children's Hospital for Wales, University Hospital, Cardiff, UK.; Bertolini P; Pediatric Hematology-Oncology Unit University-Hospital of Parma, Parma, Italy.; Bisogno G; Department of Women's and Children's Health, University of Padua, Padua, Italy.; Pediatric Hematology Oncology Division, University Hospital of Padua, Padua, Italy.; Bouhamama A; Service de Radiologie Interventionnelle Oncologique, Centre Léon Bérard, Lyon, France.; Caro-Dominguez P; Pediatric Radiology Unit, Department of Radiology, Hospital Universitario Virgen del Rocío, Avenida Manuel Siurot S/N, Seville, Spain.; Charon V; Radiology Department, CHU Rennes, Rennes, France.; Coma A; Paediatric Radiology Unit, Vall d´Hebron Hospital Campus, Barcelona, Spain.; Dandis R; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.; Devalck C; Department of Hemato-Oncology, HUB, ULB, HUDERF, Brussels, Belgium.; De Donno G; Image Sciences Institute, UMC Utrecht, Utrecht, The Netherlands.; Ferrari A; Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.; Fiocco M; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.; Mathematical Institute, Leiden University, Leiden, The Netherlands.; Gallego S; Pediatric Oncology Department, Vall d'Hebron Hospital, Barcelona, Spain.; Giraudo C; Unit of Advanced Clinical and Translational Imaging, Department of Medicine-DIMED, University of Padova, 35122, Padua, Italy.; Glosli H; Department of Paediatric Research, Division of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.; Ter Horst SAJ; Department of Radiology and Nuclear Medicine, Wilhelmina Children's Hospital, UMC Utrecht, Utrecht, The Netherlands.; Jenney M; Paediatric Oncology, Cardiff and Vale UHB, Cardiff, UK.; Klein WM; Department of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands.; Leemans A; Image Sciences Institute, UMC Utrecht, Utrecht, The Netherlands.; Leseur J; Service de Radiothérapie, Centre Eugène Marquis, Rennes, France.; Mandeville HC; Department of Radiotherapy, The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, UK.; McHugh K; Department of Radiology, Great Ormond Street Hospital for Children, NHS Foundation Trust, London, UK.; Merks JHM; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.; Division of Imaging and Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.; Minard-Colin V; Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.; Moalla S; Department of Imaging, Institut Gustave Roussy, Villejuif, France.; Morosi C; Diagnostic and Interventional Radiology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.; Orbach D; SIREDO Oncology Center (Care, Innovation and Research for Children and AYA With Cancer), Institut Curie, PSL Research University, Paris, France.; Ording Muller LS; Department of Radiology and Intervention Unit for Paediatric Radiology, Oslo University Hospital, Ullevål, Norway.; Pace E; Department of Radiology, The Royal Marsden NHS Foundation Trust, London, UK.; Di Paolo PL; Department of Radiology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.; Perruccio K; Pediatric Hematology Oncology, Azienda Ospedaliera Universitaria, Ospedale Santa Maria Della Misericordia, Perugia, Italy.; Quaglietta L; Neuro-Oncology Unit, Department of Paediatric Oncology, Santobono-Pausilipon Children's Hospital, Naples, Italy.; Renard M; Department of Paediatric Hemato-Oncology, University Hospital Leuven, Louvain, Belgium.; van Rijn RR; Department of Radiology and Nuclear Medicine, Amsterdam UMC Location University of Amsterdam, Amsterdam, the Netherlands.; Ruggiero A; Pediatric Oncology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.; Sirvent SI; Pediatric Radiology Department, Hospital Niño Jesús, Madrid, Spain.; De Luca A; Image Sciences Institute, UMC Utrecht, Utrecht, The Netherlands.; Department of Neurology, UMC Utrecht Brain Center, UMC Utrecht, Utrecht, The Netherlands.; Schoot RA; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.

Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 0365332 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1998 (Electronic) Linking ISSN: 03010449 NLM ISO Abbreviation: Pediatr Radiol Subsets: MEDLINE

Mantello G; Radiotherapy Department, Azienda Ospedaliero Universitaria delle Marche, Via Conca 71, 60126, Ancona, Italy.; Galofaro E; Radiotherapy Department, Azienda Ospedaliero Universitaria delle Marche, Via Conca 71, 60126, Ancona, Italy. elena.galofaro@ospedaliriuniti.marche.it.; Caravatta L; Department of Radiation Oncology, SS Annunziata Hospital, Chieti, Italy.; Di Carlo C; Radiotherapy Department, Azienda Ospedaliero Universitaria delle Marche, Via Conca 71, 60126, Ancona, Italy.; Montrone S; Department of Radiotherapy, Pisa University, Pisa, Italy.; Arpa D; IRCCS Istituto Scientifico Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Radiotherapy Unit, Meldola, Italy.; Chiloiro G; Departments of Radiation Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.; De Paoli A; Division of Radiation Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.; Donato V; Radiation Oncology Division, Oncology and Speciality Medicine Department, San Camillo-Forlanini Hospital, Rome, Italy.; Gambacorta MA; Departments of Radiation Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.; Genovesi D; Department of Radiation Oncology, SS Annunziata Hospital, Chieti, Italy.; Lupattelli M; Radiation Oncology Section, University of Perugia and Perugia General Hospital, Perugia, Italy.; Macchia G; Radiotherapy Unit, Gemelli Molise Hospital, Catholic University of Sacred Heart, Campobasso, Italy.; Montesi G; Radiotherapy Unit, ULSS5, Rovigo, Italy.; Niespolo RM; Radiotherapy Unit, Azienda Ospedaliera San Gerardo, Monza, Italy.; Palazzari E; Division of Radiation Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.; Pontoriero A; Radiation Oncology Unit, Department of Biomedical, Dental Science and Morphological and Functional Images, University of Messina, Messina, Italy.; Scricciolo M; UOC di Radioterapia Oncologica Mestre, Ospedale dell'Angelo, Venice, Mestre, Italy.; Valvo F; Fondazione CNAO, National Center of Oncological Hadrontherapy, Pavia, Italy.; Franco P; Department of Translational Medicine, Department of Radiation Oncology, Maggiore Della Carità University Hospital, University of Eastern Piedmont, Novara, Italy.

Publisher: Springer Milan Country of Publication: Italy NLM ID: 0177625 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1826-6983 (Electronic) Linking ISSN: 00338362 NLM ISO Abbreviation: Radiol Med Subsets: MEDLINE

Recher, Christian ; Hospital, Marie-Anne ; Leguay, Thibaut ; Carre, Martin ; Orvain, Corentin ; Bonmati, Caroline ; Raffoux, Emmanuel ; Simand, Celestine ; Guieze, Romain ; Frayfer, Jamilé ; Lambert, Juliette ; Chantepie, Sylvain ; Bernard, Marc ; Peterlin, Pierre ; Alexis, Magda ; Turlure, Pascal ; Pautas, Cecile ; Bertoli, Sarah ; Gabellier, Ludovic ; Forcade, Edouard ; Duployez, Nicolas ; Luquet, Isabelle ; Penther, Dominique ; Celli-Lebras, Karine ; Mineur, Ariane ; Gardin, Claude ; Ifrah, Norbert ; Vey, Norbert ; Peffault De Latour, Regis ; Dumas, Pierre-Yves ; Delabesse, Eric ; Preudhomme, Claude ; Hamel, Jean-François ; Dombret, Herve ; Pigneux, Arnaud ; Mathilde, Hunault-Berger ; De Botton, Stephane

In Blood 3 November 2025 146 Supplement 1:881-881

Halimi, Jean-Michel; Sarafidis, Pantelis; Azizi, Michel; Bilo, Grzegorz; Burkard, Thilo; Bursztyn, Michael; Camafort, Miguel; Chapman, Neil; Cottone, Santina; de Backer, Tine; Deinum, Jaap; Delmotte, Philippe; Dorobantu, Maria; Doumas, Michalis; Dusing, Rainer; Duly-Bouhanick, Béatrice; Fauvel, Jean-Pierre; Fesler, Pierre; Gaciong, Zbigniew; Gkaliagkousi, Eugenia

Blood Pressure. Aug2024, Vol. 33 Issue 1, p1-10. 10p.

Chartier KG; School of Social Work, Virginia Commonwealth University, 1000 Floyd Avenue, Richmond, VA 23284, USA.; Virginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University, 800 East Leigh Street, Richmond, VA 23298, USA.; Montemayor BN; Department of Health Behavior, School of Public Health, Texas A&M University, College Station, TX 77843, USA.; de Araujo J; School of Social Work, Virginia Commonwealth University, 1000 Floyd Avenue, Richmond, VA 23284, USA.; Hassan A; Department of Health Behavior, School of Public Health, Texas A&M University, College Station, TX 77843, USA.; On Behalf Of The Spit For Science Working Group; Cohort and Registry Administration Core, Virginia Commonwealth University, 800 East Leigh Street, Richmond, VA 23298, USA.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101238455 Publication Model: Electronic Cited Medium: Internet ISSN: 1660-4601 (Electronic) Linking ISSN: 16604601 NLM ISO Abbreviation: Int J Environ Res Public Health Subsets: MEDLINE

Hillmen, P; Gribben, J G; Follows, G A; Milligan, D W; Sayala, H A; Moreton, P; Oscier, D; Dearden, C E; Kennedy, D B; Pettitt, A R; Nathwani, A; Cohen, D; Gregory, W M; Rawstron, A C; Hayward, C RW; Pocock, C

British Journal of Haematology. May 01, 2010 149 Sup 1:2-2

Samuel L; Department of Communication University of Delaware Newark Delaware USA.; Kuijpers K; Department of Communication University of Delaware Newark Delaware USA.; Maloney EK; Department of Communication University of Delaware Newark Delaware USA.; Langbaum JB; Banner Alzheimer's Institute Phoenix Arizona USA.; Bleakley A; Department of Communication University of Delaware Newark Delaware USA.

Publisher: Wiley on behalf of the Alzheimer's Association Country of Publication: United States NLM ID: 101650118 Publication Model: eCollection Cited Medium: Internet ISSN: 2352-8737 (Electronic) Linking ISSN: 23528737 NLM ISO Abbreviation: Alzheimers Dement (N Y) Subsets: PubMed not MEDLINE

Ljungman, P; Spanjaart, AM; Tridello, G; Knelange, N; de, la Camara R; Kersten, MJ; Mielke, S

OPEN FORUM INFECTIOUS DISEASES. 10(Supplement_2)

Heslop-Harrison, George ; Nakabayashi, Kazumi ; Espinosa-Ruiz, Ana ; Robertson, Francesca ; Baines, Robert ; Thompson, Christopher R.L. ; Hermann, Katrin ; Alabadí, David ; Leubner-Metzger, Gerhard ; Williams, Robin S.B.

In Plant Communications 10 June 2024 5(6)

Contiero P; Environmental Epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.; Borgini A; Environmental Epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.; International Society of Doctors for Environment (ISDE), 52100 Arezzo, Italy.; Bertoldi M; Environmental Epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.; Abita A; UOC Qualità dell'Aria, ARPA Sicilia, 90146 Palermo, Italy.; Cuffari G; Reporting Ambientale, Salute e Ambiente, ARPA Sicilia, 90146 Palermo, Italy.; Tomao P; Inail-Dipartimento di Medicina, Epidemiologia, Igiene del Lavoro ed Ambientale, Monte Porzio Catone, 00078 Rome, Italy.; D'Ovidio MC; Inail-Dipartimento di Medicina, Epidemiologia, Igiene del Lavoro ed Ambientale, Monte Porzio Catone, 00078 Rome, Italy.; Reale S; Laboratorio Tecnologie Diagnostiche Innovative Area Biologia Molecolare, Istituto Zooprofilattico Sperimentale della Sicilia, Via Rocco Dicillo 3, 90129 Palermo, Italy.; Scibetta S; Laboratorio Tecnologie Diagnostiche Innovative Area Biologia Molecolare, Istituto Zooprofilattico Sperimentale della Sicilia, Via Rocco Dicillo 3, 90129 Palermo, Italy.; Tagliabue G; Cancer Registry Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.; Boffi R; Respiratory Disease Unit, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy.; Krogh V; Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.; Tramuto F; Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE) 'G. D'Alessandro'-University of Palermo, 90127 Palermo, Italy.; Regional Reference Laboratory of West Sicily for the Emergency of COVID-19, Clinical Epidemiology Unit, University Hospital 'Paolo Giaccone', 90127 Palermo, Italy.; Maida CM; Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE) 'G. D'Alessandro'-University of Palermo, 90127 Palermo, Italy.; Regional Reference Laboratory of West Sicily for the Emergency of COVID-19, Clinical Epidemiology Unit, University Hospital 'Paolo Giaccone', 90127 Palermo, Italy.; Mazzucco W; Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE) 'G. D'Alessandro'-University of Palermo, 90127 Palermo, Italy.; Regional Reference Laboratory of West Sicily for the Emergency of COVID-19, Clinical Epidemiology Unit, University Hospital 'Paolo Giaccone', 90127 Palermo, Italy.; Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Centre, Cincinnati, OH 45229, USA.; On Behalf Of The Sars-CoV-And Environment Working Group

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101238455 Publication Model: Electronic Cited Medium: Internet ISSN: 1660-4601 (Electronic) Linking ISSN: 16604601 NLM ISO Abbreviation: Int J Environ Res Public Health Subsets: MEDLINE

Anema F; Department of Neonatology, Emma Children's Hospital, Amsterdam University Medical Centers, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands.; Ravelli ACJ; Department of Obstetrics and Gynaecology, Amsterdam University Medical Centers, Amsterdam, the Netherlands.; Department of Medical Informatics, Amsterdam University Medical Centers, Amsterdam, the Netherlands.; Amsterdam Reproduction & Development Research Institute, Amsterdam, the Netherlands.; Onland W; Department of Neonatology, Emma Children's Hospital, Amsterdam University Medical Centers, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands.; Amsterdam Reproduction & Development Research Institute, Amsterdam, the Netherlands.; Bakker PCAM; Department of Obstetrics and Gynaecology, Amsterdam University Medical Centers, Amsterdam, the Netherlands.; Groenendaal F; Department of Neonatology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.; Rosman AN; Perined, Utrecht, the Netherlands.; Been JV; Department of Neonatal and Paediatric Intensive Care, Division of Neonatology, Erasmus MC Sophia Children's Hospital, University Medical Centre Rotterdam, Rotterdam, the Netherlands.; Department of Obstetrics and Gynaecology, Erasmus MC Sophia Children's Hospital, University Medical Centre Rotterdam, Rotterdam, the Netherlands.; Tacke CE; Department of Neonatology, Emma Children's Hospital, Amsterdam University Medical Centers, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands. c.e.tacke@amsterdamumc.nl.; Amsterdam Reproduction & Development Research Institute, Amsterdam, the Netherlands. c.e.tacke@amsterdamumc.nl.

Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7603873 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-1076 (Electronic) Linking ISSN: 03406199 NLM ISO Abbreviation: Eur J Pediatr Subsets: MEDLINE

on behalf of the Austrian Breast and Colorectal Cancer Study Group (ABCSG); Austrian Breast and Colorectal Cancer Study Group (ABCSG); Piringer, Gudrun; Burgstaller, Sonja; Thaler, Josef; Frantal, Sophie; Gnant, Michael; Fridrik, Michael; Fridrik, Alfred; Leiherer, Andreas; Zabernigg, August; Greil, Richard; Eisterer, Wolfgang; Tschmelitsch, Jörg; Lang, Alois

Supportive Care in Cancer (SUPPORT CARE CANCER), Apr2018; 26(4): 1345-1352. (8p)

Phase III Randomized Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Early Stage CLL With High Risk of Early Disease Progression
Abrisqueta P, Pereira A, Rozman C, Aymerich M, Gine E, Moreno C, Muntanola A, Rozman M, Villamor N, Hodgson K, Campo E, Bosch F, Montserrat E. Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience. Blood. 2009 Sep 3;114(10):2044-50. doi: 10.1182/blood-2009-04-214346. Epub 2009 Jun 24.
Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, Chang BY, Sukbuntherng J, Izumi R, Hamdy A, Hedrick E, Fowler NH. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013 Jan 1;31(1):88-94. doi: 10.1200/JCO.2012.42.7906. Epub 2012 Oct 8.
Barrientos JC, Barr PM, Flinn I, Burger JA, Salman Z, Clow F et al. Ibrutinib in combination with bendamustine and rituximab is active and tolerable in patients with relapsed/refractory CLL/SLL: final results of a phase 1b study. Blood 2013; 122: 525.[Abstract].
Beum PV, Lindorfer MA, Beurskens F, Stukenberg PT, Lokhorst HM, Pawluczkowycz AW, Parren PW, van de Winkel JG, Taylor RP. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J Immunol. 2008 Jul 1;181(1):822-32. doi: 10.4049/jimmunol.181.1.822.
Bishop GA, Haxhinasto SA, Stunz LL, Hostager BS. Antigen-specific B-lymphocyte activation. Crit Rev Immunol. 2003;23(3):149-97. doi: 10.1615/critrevimmunol.v23.i3.10.
Bleeker WK, Munk ME, Mackus WJ, van den Brakel JH, Pluyter M, Glennie MJ, van de Winkel JG, Parren PW. Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. Br J Haematol. 2008 Feb;140(3):303-12. doi: 10.1111/j.1365-2141.2007.06916.x. Epub 2007 Nov 27.
Bojarczuk K, Siernicka M, Dwojak M, Bobrowicz M, Pyrzynska B, Gaj P, Karp M, Giannopoulos K, Efremov DG, Fauriat C, Golab J, Winiarska M. B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies. Leukemia. 2014 May;28(5):1163-7. doi: 10.1038/leu.2014.12. Epub 2014 Jan 10. No abstract available.
Bosch F, Abrisqueta P, Villamor N, Terol MJ, Gonzalez-Barca E, Ferra C, Gonzalez Diaz M, Abella E, Delgado J, Carbonell F, Garcia Marco JA, Escoda L, Ferrer S, Monzo E, Gonzalez Y, Estany C, Jarque I, Salamero O, Muntanola A, Montserrat E. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol. 2009 Sep 20;27(27):4578-84. doi: 10.1200/JCO.2009.22.0442. Epub 2009 Aug 24.
Brenner H, Gondos A, Pulte D. Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century. Blood. 2008 May 15;111(10):4916-21. doi: 10.1182/blood-2007-12-129379. Epub 2008 Feb 28.
Burger JA. Nurture versus nature: the microenvironment in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2011;2011:96-103. doi: 10.1182/asheducation-2011.1.96.
Burger JA, Keating MJ, Wierda WG, Hartmann E, Hoellenriegel J, Rosin NY, de Weerdt I, Jeyakumar G, Ferrajoli A, Cardenas-Turanzas M, Lerner S, Jorgensen JL, Nogueras-Gonzalez GM, Zacharian G, Huang X, Kantarjian H, Garg N, Rosenwald A, O'Brien S. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2014 Sep;15(10):1090-9. doi: 10.1016/S1470-2045(14)70335-3. Epub 2014 Aug 20.
Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O'Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ; RESONATE-2 Investigators. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med. 2015 Dec 17;373(25):2425-37. doi: 10.1056/NEJMoa1509388. Epub 2015 Dec 6.
Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, O'Brien S. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013 Jul 4;369(1):32-42. doi: 10.1056/NEJMoa1215637. Epub 2013 Jun 19.
Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P; RESONATE Investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014 Jul 17;371(3):213-23. doi: 10.1056/NEJMoa1400376. Epub 2014 May 31.
Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR, Hillmen P, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Johnson D, Huang J, Wang X, Kaptein A, Lannutti BJ, Covey T, Fardis M, McGreivy J, Hamdy A, Rothbaum W, Izumi R, Diacovo TG, Johnson AJ, Furman RR. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2016 Jan 28;374(4):323-32. doi: 10.1056/NEJMoa1509981. Epub 2015 Dec 7.
Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011 May 12;117(19):5019-32. doi: 10.1182/blood-2011-01-293050. Epub 2011 Feb 7.
Cheson BD, Byrd JC, Rai KR, Kay NE, O'Brien SM, Flinn IW, Wiestner A, Kipps TJ. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol. 2012 Aug 10;30(23):2820-2. doi: 10.1200/JCO.2012.43.3748. Epub 2012 Jul 9. No abstract available.
Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005 Feb 24;352(8):804-15. doi: 10.1056/NEJMra041720. No abstract available.
Coiffier B, Lepretre S, Pedersen LM, Gadeberg O, Fredriksen H, van Oers MH, Wooldridge J, Kloczko J, Holowiecki J, Hellmann A, Walewski J, Flensburg M, Petersen J, Robak T. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood. 2008 Feb 1;111(3):1094-100. doi: 10.1182/blood-2007-09-111781. Epub 2007 Nov 14.
Craxton A, Jiang A, Kurosaki T, Clark EA. Syk and Bruton's tyrosine kinase are required for B cell antigen receptor-mediated activation of the kinase Akt. J Biol Chem. 1999 Oct 22;274(43):30644-50. doi: 10.1074/jbc.274.43.30644.
Da Roit F, Engelberts PJ, Taylor RP, Breij EC, Gritti G, Rambaldi A, Introna M, Parren PW, Beurskens FJ, Golay J. Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. Haematologica. 2015 Jan;100(1):77-86. doi: 10.3324/haematol.2014.107011. Epub 2014 Oct 24.
Dighiero G, Maloum K, Desablens B, Cazin B, Navarro M, Leblay R, Leporrier M, Jaubert J, Lepeu G, Dreyfus B, Binet JL, Travade P. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med. 1998 May 21;338(21):1506-14. doi: 10.1056/NEJM199805213382104.
Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, Siehl S, Jager U, Bergmann M, Stilgenbauer S, Schweighofer C, Wendtner CM, Dohner H, Brittinger G, Emmerich B, Hallek M; German CLL Study Group. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006 Feb 1;107(3):885-91. doi: 10.1182/blood-2005-06-2395. Epub 2005 Oct 11.
Flinn IW, Neuberg DS, Grever MR, Dewald GW, Bennett JM, Paietta EM, Hussein MA, Appelbaum FR, Larson RA, Moore DF Jr, Tallman MS. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol. 2007 Mar 1;25(7):793-8. doi: 10.1200/JCO.2006.08.0762. Epub 2007 Feb 5.
Flinn IW, Byrd JC, Morrison C, Jamison J, Diehl LF, Murphy T, Piantadosi S, Seifter E, Ambinder RF, Vogelsang G, Grever MR. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood. 2000 Jul 1;96(1):71-5.
Gribben JG, O'Brien S. Update on therapy of chronic lymphocytic leukemia. J Clin Oncol. 2011 Feb 10;29(5):544-50. doi: 10.1200/JCO.2010.32.3865. Epub 2011 Jan 10.
Gururajan M, Jennings CD, Bondada S. Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma. J Immunol. 2006 May 15;176(10):5715-9. doi: 10.4049/jimmunol.176.10.5715.
Hagenbeek A, Gadeberg O, Johnson P, Pedersen LM, Walewski J, Hellmann A, Link BK, Robak T, Wojtukiewicz M, Pfreundschuh M, Kneba M, Engert A, Sonneveld P, Flensburg M, Petersen J, Losic N, Radford J. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood. 2008 Jun 15;111(12):5486-95. doi: 10.1182/blood-2007-10-117671. Epub 2008 Apr 4.
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O'Brien S, Robak T, Seymour JF, Kipps TJ. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018 Jun 21;131(25):2745-2760. doi: 10.1182/blood-2017-09-806398. Epub 2018 Mar 14.
Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grunhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jager U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Buhler A, Winkler D, Zenz T, Bottcher S, Ritgen M, Mendila M, Kneba M, Dohner H, Stilgenbauer S; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010 Oct 2;376(9747):1164-74. doi: 10.1016/S0140-6736(10)61381-5.
Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, Flynn J, Jones J, Blum KA, Buggy JJ, Hamdy A, Johnson AJ, Byrd JC. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011 Jun 9;117(23):6287-96. doi: 10.1182/blood-2011-01-328484. Epub 2011 Mar 21.
Hoechstetter MA, Busch R, Eichhorst B, Buhler A, Winkler D, Eckart MJ, Vehling-Kaiser U, Schimke H, Jager U, Hurtz HJ, Hopfinger G, Hartmann F, Fuss H, Abenhardt W, Blau I, Freier W, Muller L, Goebeler M, Wendtner CM, Bahlo J, Fischer K, Bentz M, Emmerich B, Dohner H, Hallek M, Stilgenbauer S. Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group. Leukemia. 2017 Dec;31(12):2833-2837. doi: 10.1038/leu.2017.246. Epub 2017 Aug 14. No abstract available.
Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li S, Pan Z, Thamm DH, Miller RA, Buggy JJ. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80. doi: 10.1073/pnas.1004594107. Epub 2010 Jul 6.
Kohrt HE, Sagiv-Barfi I, Rafiq S, Herman SE, Butchar JP, Cheney C, Zhang X, Buggy JJ, Muthusamy N, Levy R, Johnson AJ, Byrd JC. Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood. 2014 Mar 20;123(12):1957-60. doi: 10.1182/blood-2014-01-547869. No abstract available.
Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer. 2005 Apr;5(4):251-62. doi: 10.1038/nrc1589.
Langerbeins P, Bahlo J, Rhein C, Cramer P, Pflug N, Fischer K, Stilgenbauer S, Kreuzer KA, Wendtner CM, Eichhorst B, Hallek M. The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression. Future Oncol. 2015;11(13):1895-903. doi: 10.2217/fon.15.95.
Meeker T, Lowder J, Cleary ML, Stewart S, Warnke R, Sklar J, Levy R. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. N Engl J Med. 1985 Jun 27;312(26):1658-65. doi: 10.1056/NEJM198506273122602.
Miller MD, Paradis CF, Houck PR, Mazumdar S, Stack JA, Rifai AH, Mulsant B, Reynolds CF 3rd. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res. 1992 Mar;41(3):237-48. doi: 10.1016/0165-1781(92)90005-n.
National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Non-Hodgkin's Lymphomas. Version I.2012. NCCN.org
O'Brien SM, Kantarjian HM, Cortes J, Beran M, Koller CA, Giles FJ, Lerner S, Keating M. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol. 2001 Mar 1;19(5):1414-20. doi: 10.1200/JCO.2001.19.5.1414.
O'Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, Grant B, Richards DA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Izumi R, Hamdy A, Chang BY, Graef T, Clow F, Buggy JJ, James DF, Byrd JC. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014 Jan;15(1):48-58. doi: 10.1016/S1470-2045(13)70513-8. Epub 2013 Dec 10.
Pawluczkowycz AW, Beurskens FJ, Beum PV, Lindorfer MA, van de Winkel JG, Parren PW, Taylor RP. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J Immunol. 2009 Jul 1;183(1):749-58. doi: 10.4049/jimmunol.0900632. Epub 2009 Jun 17.
Petro JB, Rahman SM, Ballard DW, Khan WN. Bruton's tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement. J Exp Med. 2000 May 15;191(10):1745-54. doi: 10.1084/jem.191.10.1745.
Petro JB, Khan WN. Phospholipase C-gamma 2 couples Bruton's tyrosine kinase to the NF-kappaB signaling pathway in B lymphocytes. J Biol Chem. 2001 Jan 19;276(3):1715-9. doi: 10.1074/jbc.M009137200. Epub 2000 Oct 19.
Pflug N, Bahlo J, Shanafelt TD, Eichhorst BF, Bergmann MA, Elter T, Bauer K, Malchau G, Rabe KG, Stilgenbauer S, Dohner H, Jager U, Eckart MJ, Hopfinger G, Busch R, Fink AM, Wendtner CM, Fischer K, Kay NE, Hallek M. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood. 2014 Jul 3;124(1):49-62. doi: 10.1182/blood-2014-02-556399. Epub 2014 May 5.
Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, Keating MJ, O'Brien S, Chiorazzi N, Burger JA. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012 Feb 2;119(5):1182-9. doi: 10.1182/blood-2011-10-386417. Epub 2011 Dec 16.
Satterthwaite AB, Witte ON. The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective. Immunol Rev. 2000 Jun;175:120-7.
Shaffer AL, Rosenwald A, Staudt LM. Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol. 2002 Dec;2(12):920-32. doi: 10.1038/nri953.
Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006 Jul 1;24(19):3187-205. doi: 10.1200/JCO.2006.06.4451. Epub 2006 May 8.
Spaargaren M, Beuling EA, Rurup ML, Meijer HP, Klok MD, Middendorp S, Hendriks RW, Pals ST. The B cell antigen receptor controls integrin activity through Btk and PLCgamma2. J Exp Med. 2003 Nov 17;198(10):1539-50. doi: 10.1084/jem.20011866. Epub 2003 Nov 10.
Surveillance Epidemiology and End Results (SEER), NCI, US National Institutes of Health, Fast Stats; Statistics Stratified by Cancer Site, 2010.
Tam CS, O'Brien S, Wierda W, Kantarjian H, Wen S, Do KA, Thomas DA, Cortes J, Lerner S, Keating MJ. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008 Aug 15;112(4):975-80. doi: 10.1182/blood-2008-02-140582. Epub 2008 Apr 14.
Teeling JL, French RR, Cragg MS, van den Brakel J, Pluyter M, Huang H, Chan C, Parren PW, Hack CE, Dechant M, Valerius T, van de Winkel JG, Glennie MJ. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood. 2004 Sep 15;104(6):1793-800. doi: 10.1182/blood-2004-01-0039. Epub 2004 Jun 1.
Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, French RR, van Meerten T, Ebeling S, Vink T, Slootstra JW, Parren PW, Glennie MJ, van de Winkel JG. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. 2006 Jul 1;177(1):362-71. doi: 10.4049/jimmunol.177.1.362.
Tomlinson MG, Woods DB, McMahon M, Wahl MI, Witte ON, Kurosaki T, Bolen JB, Johnston JA. A conditional form of Bruton's tyrosine kinase is sufficient to activate multiple downstream signaling pathways via PLC Gamma 2 in B cells. BMC Immunol. 2001;2:4. doi: 10.1186/1471-2172-2-4. Epub 2001 Jun 8.
Welch HG, Albertsen PC, Nease RF, Bubolz TA, Wasson JH. Estimating treatment benefits for the elderly: the effect of competing risks. Ann Intern Med. 1996 Mar 15;124(6):577-84. doi: 10.7326/0003-4819-124-6-199603150-00007.
Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Robak T, Furman RR, Hillmen P, Trneny M, Dyer MJ, Padmanabhan S, Piotrowska M, Kozak T, Chan G, Davis R, Losic N, Wilms J, Russell CA, Osterborg A; Hx-CD20-406 Study Investigators. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010 Apr 1;28(10):1749-55. doi: 10.1200/JCO.2009.25.3187. Epub 2010 Mar 1.
Wierda WG, Kipps TJ, Durig J, Griskevicius L, Stilgenbauer S, Mayer J, Smolej L, Hess G, Griniute R, Hernandez-Ilizaliturri FJ, Padmanabhan S, Gorczyca M, Chang CN, Chan G, Gupta I, Nielsen TG, Russell CA; 407 Study Investigators. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood. 2011 Jun 16;117(24):6450-8. doi: 10.1182/blood-2010-12-323980. Epub 2011 Apr 15.

Tong, Cen ; Jia, Yong ; Hu, Haifei ; Zeng, Zhanghui ; Chapman, Brett ; Li, Chengdao

In Plant Communications 13 January 2025 6(1)

Borghetti P; Department of Radiation Oncology, Istituto del Radio O. Alberti, Spedali Civili Hospital and Brescia University, Brescia, Italy.; Bonù ML; Department of Radiation Oncology, Istituto del Radio O. Alberti, Spedali Civili Hospital and Brescia University, Brescia, Italy. marcolorenzo89.mlb@gmail.com.; Giubbolini R; Radiotherapy Unit, Oncology and Hematology Department, University Hospital of Modena, Modena, Italy.; Levra NG; Department of Radiation Oncology, Sacro Cuore Hospital, Negrar, Italy.; Mazzola R; Department of Radiation Oncology, Sacro Cuore Hospital, Negrar, Italy.; Perna M; Department of Oncology Radiation Therapy Unit, Careggi University Hospital, Florence, Italy.; Visani L; Department of Oncology Radiation Therapy Unit, Careggi University Hospital, Florence, Italy.; Meacci F; Department of Oncology Radiation Therapy Unit, Careggi University Hospital, Florence, Italy.; Taraborrelli M; Radiotherapy Unit, SS Annunziata Hospital - G. D'annunzio University, Chieti, Italy.; Triggiani L; Department of Radiation Oncology, Istituto del Radio O. Alberti, Spedali Civili Hospital and Brescia University, Brescia, Italy.; Franceschini D; Department of Radiotherapy and Radiosurgery, Humanitas Research Hospital and Cancer Center, Milan, Rozzano, Italy.; Greco C; Departement of Radiation Oncology, Campus Bio-Medico University, Rome, Italy.; Bruni A; Radiotherapy Unit, Oncology and Hematology Department, University Hospital of Modena, Modena, Italy.; Magrini SM; Department of Radiation Oncology, Istituto del Radio O. Alberti, Spedali Civili Hospital and Brescia University, Brescia, Italy.; Scotti V; Department of Oncology Radiation Therapy Unit, Careggi University Hospital, Florence, Italy.

Publisher: Springer Milan Country of Publication: Italy NLM ID: 0177625 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1826-6983 (Electronic) Linking ISSN: 00338362 NLM ISO Abbreviation: Radiol Med Subsets: MEDLINE

Taran, Shaurya; Citerio, Giuseppe; Taccone, Fabio S.; Rezoagli, Emanuele; Liu, Kuan; McCredie, Victoria A.; Laffey, John G.; Calabro, Lorenzo; Patroniti, Nicolo A.; Graziano, Francesca; Rebora, Paola; Robba, Chiara; Adhikari, Neill K. J.; on behalf of the VENTIBRAIN study group; Hu, Chenggong; Liu, Tingting; Dong, Meiling; Yang, Wei; Yang, Ying; Lv, Yinxia

Intensive Care Medicine; Jan2026, Vol. 52 Issue 1, p31-41, 11p

Lung Cancer. 11:99-99

Olliges, Elisabeth; Bührlen, Bernhard; Fischer, Franz; Boesecke, Christoph; Kümmerle, Tim; Schneider, Jochen; Weidlich, Simon; Cordes, Christiane; Heiken, Hans; Stellbrink, Hans-Jürgen; Krznaric, Ivanka; Scholten, Stefan; Jensen, Björn Erik-Ole; Wolf, Eva; Ronel, Joram; Spinner, Christoph D.; on behalf of the DUALIS STUDY GROUP

AIDS Care (AIDS CARE), Jun2022; 34(6): 698-707. (10p)